Study Shows two-thirds of the Population Is Hypnotizable
Study Shows two-thirds of the Population Is Hypnotizable—Recent Genetic Findings Reveal Why
SAN FRANCISCO, March 20, 2025 /PRNewswire/ -- Reveri, the world-leading self-hypnosis app co-founded by Dr. David Spiegel—Associate Chair of Psychiatry at Stanford University—announced compelling new findings from an analysis of 100,000+ users, revealing that 60.3% of individuals are hypnotizable, with 35% falling into the "highly hypnotizable" category. In parallel, recent genetic research from Dr. Spiegel's lab shows that hypnotizability is influenced by specific gene variants—particularly in the catechol-O-methyltransferase (COMT) gene— explaining why some people respond more quickly to self-hypnosis.
Developed from 45+ years of research and backed by 400+ peer-reviewed studies, Dr. Spiegel's self-hypnosis methodologies help people achieve fast, drug-free relief from pain, stress and insomnia, and conquer detrimental habits such as smoking or vaping. Central to this approach is his interactive hypnotizability test, a 10-minute interactive audio-guided session that leads users through steps and questions designed to challenge their consciousness to determine how hypnotizable they are.
"Our research shows that self-hypnosis, when grounded in rigorous science, can make a profound difference in people's lives," said Dr. David Spiegel.
Why This Matters
- 60% of Users Are Hypnotizable: Large-scale data confirms a wide swath of the population can benefit from self-hypnosis.
- Genes Come Into Play: Dr. Spiegel's COMT gene research reveals that genetics can significantly influence how quickly someone experiences hypnotic effects.
- Drug-Free Relief: Self-hypnosis provides a side-effect-free option for managing pain, stress, or insomnia.
- Rapid Results: Many users experience positive outcomes within just a few sessions, sometimes immediately.
- Accessible Tools: The hypnotizability test and a range of self-hypnosis sessions are available in the Reveri app, which offers a free trial.
About Reveri
Reveri is the brainchild of Dr. David Spiegel. By combining clinical rigor with a user-friendly platform, Reveri enables people to harness their innate capacity to address challenges like stress, anxiety, pain, and poor sleep. Users can experience meaningful results in just minutes, all backed by decades of research and emerging genetic discoveries.
For more information or to schedule an interview, please contact:
Dan Stern, CEO, Reveri
About Dr. David Spiegel
Dr. David Spiegel is the Associate Chair of Psychiatry at Stanford University. He has authored more than 400 peer-reviewed articles, furthering the scientific understanding of how hypnosis alters brain function and benefits individuals.
View original content:https://www.prnewswire.com/news-releases/study-shows-two-thirds-of-the-population-is-hypnotizable-302406462.html
SOURCE Reveri Health, Inc